Search Results

You are looking at 31 - 40 of 1,744 items for :

  • "chemotherapy" x
Clear All
Full access

Sumer K. Wallace, Jeff F. Lin, William A. Cliby, Gary S. Leiserowitz, Ana I. Tergas and Robert E. Bristow

) view/print certificate. Release date: May 12, 2016; Expiration date: May 12, 2017 Learning Objectives Upon completion of this activity, participants will be able to: Identify risk factors associated with refusal of recommended chemotherapy

Full access

Andrew G. Robinson, Xuejiao Wei, William J. Mackillop, Yingwei Peng and Christopher M. Booth

will present with advanced disease or develop metastatic disease after presentation. 1 For patients with advanced disease, clinical trials suggest that multiagent cisplatin-based chemotherapy is associated with improved survival. Regimens studied

Full access

Gary H. Lyman and Jessica Malone Kleiner

discussed in the article or their competitors. References 1. Dale DC McCarter GC Crawford J . Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials . J Natl Compr Canc Netw 2003 ; 1 : 440

Full access

Renata R. Urban, Hao He, Rafael Alfonso-Cristancho, Melissa M. Hardesty and Barbara A. Goff

that they treat. In preparation for payment reform, ASCO developed a bundled payment model for the treatment of patients with cancer using chemotherapy. 2 , 3 Ovarian cancer is a complex disease requiring surgery and chemotherapy to achieve the best

Full access

Alison K. Conlin and Andrew D. Seidman

Genentech Inc. References 1. Early Breast Cancer Trialists' Collaborative Group . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials . Lancet 2005

Full access

Vivek Verma, Pamela K. Allen, Charles B. Simone II, Hiram A. Gay and Steven H. Lin

malignancies. 5 Moreover, a median overall survival (OS) of 2 to 3 years can be achieved for select patients with oligometastatic M1 NPC receiving palliative chemotherapy and/or those with good response to systemic therapy. 6 – 8 In light of these

Full access

Richard Li, Wei-Hsien Hou, Joseph Chao, Yanghee Woo, Scott Glaser, Arya Amini, Rebecca A. Nelson and Yi-Jen Chen

dissection, has been established as the primary curative treatment modality for locally advanced gastric cancer. 3 , 4 Perioperative chemotherapy, adjuvant chemotherapy, or adjuvant chemoradiation (CRT) are given in conjunction with surgery based on data

Full access

Eric J. Roeland, Kathryn J. Ruddy, Thomas W. LeBlanc, Ryan D. Nipp, Gary Binder, Silvia Sebastiani, Ravi Potluri, Luke Schmerold, Eros Papademetriou, Lee Schwartzberg and Rudolph M. Navari

Background Despite the availability of evidence-based guidelines for the prevention of chemotherapy-induced nausea and vomiting (CINV), adherence to these guidelines remains suboptimal. In addition to the impact on quality of life (QoL), poorly

Full access

Andrea Cercek, Karyn A. Goodman, Carla Hajj, Emily Weisberger, Neil H. Segal, Diane L. Reidy-Lagunes, Zsofia K. Stadler, Abraham J. Wu, Martin R. Weiser, Philip B. Paty, Jose G. Guillem, Garrett M. Nash, Larissa K. Temple, Julio Garcia-Aguilar and Leonard B. Saltz

those of local recurrence. 1 , 2 The current standard management for stage II (T3/T4N0) and stage III (TanyN1/N2) rectal cancer is neoadjuvant chemoradiotherapy, followed by surgery, with 4 months of adjuvant systemic chemotherapy given at the end. 1

Full access

Jagar Jasem, Christine M. Fisher, Arya Amini, Elena Shagisultanova, Rachel Rabinovitch, Virginia F. Borges, Anthony Elias and Peter Kabos

Background Adjuvant chemotherapy was once considered the standard of care for patients with primary breast cancer with tumors >1 cm regardless of axillary lymph node involvement. 1 – 3 However, given disease recurrence rates of <20% by 10